CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 1, 2014
Result type: Reports
Project Number: SR0379-000
Product Line: Reimbursement Review

Generic Name: Ivacaftor

Brand Name: Kalydeco

Manufacturer: Vertex Pharmaceuticals Canada

Therapeutic Area: Cystic Fibrosis, CFTR gating mutations

Indications: Cystic Fibrosis (CFTR gating mutations)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 19, 2014

Recommendation Type: List with criteria/condition